Trinity Nuclein Series C Investors
Trinity Nuclein Series C Investors LLC
Nuclein is an innovative medical device company that specializes in the development of rapid diagnostic testing technologies. Founded in 2017 and based in Austin, Texas, Nuclein addresses the critical need for fast, accurate, and accessible testing for infectious diseases.
Products & Team
DASH® Rapid PCR System
The DASH® Rapid PCR System is a cutting-edge diagnostic tool that enables healthcare professionals to deliver lab-quality PCR test results in a rapid timeframe of just 15 minutes. Designed for use at the point of care, this system significantly enhances the speed of infectious disease diagnosis, providing immediate results to both practitioners and patients.
The DASH® Rapid PCR System meets the urgent need for accessible and timely infectious disease diagnostics, enabling healthcare providers to make informed decisions rapidly and improve patient outcomes.
Current testing methods are often slow, complex, and require laboratory settings. Nuclein addresses these challenges by simplifying the testing process to a quick and accessible solution.